Review Articles
Vol. 8 (2016): Review, Original Articles, Case Reports
INFLUENZA AND PNEUMOCOCCAL VACCINATION IN HEMATOLOGICAL MALIGNANCIES: A SYSTEMATIC REVIEW OF EFFICACY, EFFECTIVENESS AND SAFETY
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: August 8, 2016
Accepted: August 11, 2016
Accepted: August 11, 2016
7742
Views
1437
Downloads
3131
HTML
Hematology,
Infectious Diseases
Authors
Background The risk of getting influenza and pneumococcal disease is higher in cancer patients and serum antibody levels tend to be lower in patients with hematological malignancy.
Objective To asses flu and pneumococcal vaccinations efficacy, effectiveness and safety in onco-hematological patients.
Methods Two systematic reviews and possible meta-analysis were conducted to summarize the results of all primary study in scientific literature about flu and pneumococcal vaccine in onco-hematological patients. Literature searches were performed using Pub-Med and Scopus databases. StatsDirect 2.8.0 was used for the analysis.
Results 23 and 26 studies were collected respectively for flu and pneumococcal vaccinations. Protection rate of booster dose was 30% (95% CI = 6.2- 61%) for H1N1. Pooled prevalence protection rate of H3N2 and B was available for meta-analysis only for first dose, 42.6% (95% CI = 23.2 – 63.3 %) and 39.6 % (95% CI = 26%- 54.1%) for H3N2 and B, respectively.
Response rate of booster dose resulted 35% (95% CI = 19.7-51.2%) for H1N1, 23% (95% CI = 16.6-31.5%) for H3N2, 29% (95% CI = 21.3- 37%) for B.
Conclusion Despite low rate of response, flu and pneumococcal vaccines are worthwhile for patients with hematological malignancies. Patients undergoing chemotherapy in particular rituximab, splenectomy, transplant recipient had lower and impaired response. No serious adverse events were reported for both vaccines.
Downloads
Download data is not yet available.
Citations
Yousuf HM, Englund J, Couch R, Rolston K, Luna M, Goodrich J, Lewis V, Mirza NQ, Andreeff M, Koller C, Elting L, Bodey GP, Whimbey E. Influenza among hospitalized adults with leukemia. Clin Infect Dis. 1997;24:1095-1099.
Centers for Disease Control and Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices ACIP. MMWR. 2009;58:1–52. www.cdc.gov/mmwr/preview
Mackay HJ, McGee J, Villa D, Gubbay JB, Tinker LM, Shi L, Kuruvilla J, Wang L, MacAlpine K, Oza AM. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol. 201;50:212-216
WHO. Relevé épidémiologique hebdomadaire. Pneumococcal vaccinesWHO position paper – 2012. Wkly Epidemiol Rec 2012;87:129–144
Hamborsky J, Kroger Eds In: A Epidemiology and prevention of vaccine-preventable diseases, E-Book: The Pink Book. Public Health Foundation. 2015.
Moher, D, Liberati A, Tetzlaff J , Altman, D G Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009. 151;264-269
Wells GA, Shea B, O’Connell D, Peterson JEA, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (last accessed 2016.07.14)
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12
Michell DR, Ruben FL, Gravenstein S. Immuogenicity and safety of inactivated influenza vaccine in young children in 2003–2004. Pediatr Infect Dis. J 2005;24:925–927.
Bridges CB, Katz JM, Levandowski RA, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. , eds. Vaccines. 5th ed.Philadelphia, PA: Saunders Elsevier; 2008:259-290
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14:951-957.
Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G.. Antibody Response to a Two-Dose Influenza Vaccine Regimen in Adult Lymphoma Patients on Chemotherapy. Eur J Clin Microbiol Infect Dis. 1993;12:778-782.
Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH.. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenza type B in patients with multiple myeloma. Br J Cancer. 2000;82:1261-1265.
Rapezzi D, Sticchi L, Racchi O, Mangerini R, Ferraris AM, Gaetani GF. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol. 2003;70:225-230.
de Lavallade H1, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani K. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96:307-314
Brydak LB, Machała M, Centkowski P, Warzocha K, Biliński P. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine. 2006;24(44-46):6620-6623
Dotan A, Ben-Shimol S, Fruchtman Y, Avni-Shemer Y, Kapelushnik J, Ben-Harush M, Givon-Lavi N, Leibovitz E, Greenberg D. Influenza A/H1N1 in Pediatric Oncology Patients. J Pediatr Hematol Oncol. 2014;36:e271-4
Sanada Y, Yakushijin K, Nomura T, Chayahara N, Toyoda M, Minami Y, Kiyota N, Mukohara T, Kawamoto S, Ito M, Matsuoka H, Minami H. A prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy. Jpn J Clin Oncol. 2016;46:448-452
van der Velden AM, Mulder AH, Hartkamp A, Diepersloot RJ, van Velzen-Blad H, Biesma DH.Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med. 2001;12:420-424.
Ljungman P, Nahi H, Linde A.Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol. 2005;130:96-98
Bate J, Yung CF, Hoschler K, Sheasby L, Morden J, Taj M, Heath PT, Miller E. Immunogenicity of Pandemic (H1N1) 2009 Vaccine in Children with Cancer in the United Kingdom. Clin Infect Dis. 2010;51:e95-104
Mackay HJ, McGee J, Villa D, Gubbay JB, Tinker LM, Shi L, Kuruvilla J, Wang L, MacAlpine K, Oza AM.Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol. 2011 Mar;50:212-216.
Cherif H, Höglund M, Pauksens K. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients. Eur J Haematol. 2013;90(5):413-419
Ide Y, Imamura Y, Ohfuji S, Fukushima W, Ide S, Tsutsumi C, Koga M, Maeda K, Hirota Y. Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies. Hum Vaccin Immunother. 2014;10:2387-2394
Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. Dose-Related Safety and Immunogenicity of Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-Blind, Controlled Trial in Adult Patients with Non-Hodgkin B Cell Lymphoma. J Infect Dis. 2006;194:1394-1397
Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, Sertoli MR, Balleari E, Racchi O, Messina M, Caltabiano G, Icardi G, Durando P, Marincola FM, Boccardo F, Ferrarini M, Ansaldi F, De Maria A. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011;186:6044-6055.
Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, Dray L, Djian E, Strauss-Liviatan N, Grotto I, Wolf DG, Or R. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 2011: 29:1777-1782.
Esposito S, Cecinati V, Scicchitano B, Delvecchio GC, Santoro N, Amato D, Pelucchi C, Jankovic M, De Mattia D, Principi N. Impact of influenza-like illness and effectiveness of influenza vaccination in oncohematological children who have completed cancer therapy. Vaccine. 2010;28:1558-1565.
Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Fahl Wader K, Østenstad B, Ekanger R, Meyer P, Kolstad1 A. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011; 118:6769-6771
Porter CC, Edwards KM, Zhu Y, Frangoul H.. Immune Responses to Influenza Immunization in Children Receiving Maintenance Chemotherapy for Acute Lymphoblastic Pediatr Blood Cancer. 2004;42:36-40.
Shahgholi E, Ehsani MA, Salamati P, Maysamie A, Sotoudeh K, Mokhtariazad T. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr Blood Cancer 2010;54:716-720.
Monkman K, Mahony J, Lazo-Langner A, Chin-Yee BH, Minuk LA. The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies. Leuk Lymphoma. 2011; 52:1736–1741
Dignani MC, Costantini P, Salgueira C, Jordán R, Guerrini G, Valledor A, Herrera F, Nenna A, Mora C, Roccia-Rossi I, Stecher D, Carbone E, Laborde A, Efron E, Altclas J, Calmaggi A, Cozzi J. Pandemic 2009 Influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study. Version 2. F1000Res. 2014 [revised 2015 Aug 25];3:22.
Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ, Molrine DC. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:213-222.
Braconier JH, Pedersen FK, Odeberg H, Rosén C. Opsonic and antibody responses to pneumococcal polysaccharide types 6A, 19F and 23F after vaccination of immunocompromised patients. Scand J Infect Dis.1984;16:161-167.
Chan CY, Molrine DC, George S, Tarbell NJ, Mauch P, Diller L, Shamberger RC, Phillips NR, Goorin, Ambrosino DM. Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2008;14:1022-1030.
Cheng FWT, Ip M, Chu YYL, Lin Z, Lee V, Shing MK Leung WK,Yuen PMP, Li, CK. Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients. Arch Dis Child. 2012;97:358-360
Cherif H, Landgren O, Konradsen HB, Kalin M, Björkhol M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine. 2006;24:75-81.
Eigenberger K, Sillaber C, Greitbauer M, Herkner H, Wolf H, Graninger W , Gattringer R, Burgmann H. Antibody responses to pneumococcal and hemophilus vaccinations in splenectomized patients with hematological malignancies or trauma. Wien Klin Wochenschr. 2007;119:228-234.
Feldman S, Malone W, Wilbur R, Schiffman G. Pneumococcal vaccination in children with acute lymphocytic leukemia. Med Pediatr Oncol. 1985;13:69-72.
Frederiksen B, Specht L, Henrichsen J, Pedersen F K, Pedersen Bjergaard J.Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. Eur J Haematol. 1989;43:45-49.
Gandhi MK, Egner W, Sizer L, Inman I, Zambon M, Craig JIO, Marcus RE. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. 2001;28.
Hartkamp A, Mulder AHL, Rijkers, GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19:1671-1677.
Hinge M, Ingels HA, Slotved HC, Mølle I. Serologic response to a 23 valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. Apmis. 2012;120:935-940.
Landgren O, Björkholm M, Konradsen HB, Söderqvist M, Nilsson B, Gustavsson A, Axdorph U, Kalin M, Grimfors, G. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med. 2004;255:664-673.
Llupià A, Vilella A, Costas L, Díez C, Torres F, Yagüe J, Massò M, Munoz A, Mensa J. Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted? Vaccine. 2012;30:2382-2386.
Meerveld-Eggink A, van der Velden AM, Ossenkoppele GJ, van de Loosdrecht A, Biesma DH, Rijkers GT. Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1523-1530.
Nordøy T, Husebekk A, Aaberge IS, Jenum PA, Samdal, HH, Flugsrud LB, Kristoffersen C, Holte H, Kvaløy S, Kolstad A. Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant. 2001;28.
Nordøy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, Kolstad, A. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Onc. 2002;19:71-78
Pao M, Papadopoulos EB, Chou J, Glenn H, Castro-Malaspina H., Jakubowski AA, Kernan NA, Perales MA, Prokop S, Scaradavou A, VanDenBrink MR, Young JW, O'Reilly RJ, Small TN Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2008;14:1022-1030.
Parkkali T, Käyhty H, Ruutu, T, Volin L, Eskola J, Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant. 1996;18:961-967
Pasiarski M, Rolinski J, Grywalska E, Stelmach Goldys A, Korona-Glowniak I, Gozdz S, Hus Iwona Malm, A. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients–preliminary report. PloS one. 2014;9:e114966
Patel SR, Ortín M, Cohen BJ, Borrow R, Irving D, Sheldon J, Heath PT. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis. 2007;44:625-634
Petrasch S, Kühnemund O, Reinacher A, Uppenkamp M, Reinert R, Schmiegel W, Lutticken R, Brittinger G. Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines. Clin Diagn Lab Immunol. 1997;4:635-638
Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000;82:1261
Shah GL, Shune L, Purtill D, Devlin S, Lauer E, Lubin M, Giralt S. Robust vaccine responses in adult and pediatric cord blood transplantation recipients treated for hematologic malignancies. Biol Blood Marrow Transplant. 2015;21:2160-2166
Siber GR, Weitzman S A, Aisenberg, AC, Weinstein HJ, Schiffman, G. Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. N Engl J Med. 1978;299(9):442-448
Sinisalo M, Aittoniemi J, Oivanen P, Käyhty, H, Ölander RM, Vilpo J. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001;114:107-110
Sinisalo M, Vilpo J, Itälä M, Väkeväinen M, Taurio J, Aittoniemi J Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007;26:82-87.
Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70:767-777
Carbone J, del Pozo N, Gallego A, Sarmiento E. Immunological risk factors forinfection after immunosuppressive and biologic therapies. Exp Rev Anti InfectTher 2011;9:405–413
Shetty AK, Winter MA. Immunization of Children Receiving Immunosuppressive Therapy for Cancer or Hematopoietic Stem Cell Transplantation. Ochsner J. 2012; 12: 228–243
Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP).. Prevention and control of influenza. Recommendation of the advisory Committee on immunization practice (ACIP). MMWR Recomm Rep. 2004 May 28;53:1-40.
American Academy of Pediatrics Committee on Infectious Diseases. Prevention of influenza: Recommendations for influenza immunization of children 2008–2009. Pediatrics 2008;122:1–18.
La Torre G, Mannocci A, Ursillo P, Bontempi C, Firenze A, Panico MG, Sferrazza A, Ronga C, D'Anna A, Amodio E, Romano N, Boccia A. Prevalence of influenza vaccination among nurses and ancillary workers in Italy: systematic review and meta analysis. Hum Vaccin. 2011 Jul;7(7):728-33. 66.Mannocci A, Di Thiene D, Abuukar N, Boccia A, La Torre G. H1N1 pandemic influenza: habits and behaviour of the nurses. A public health issue. Ann Ig. 2014 Jan-Feb;26(1):97-109
Cadeddu C, Di Thiene D, Ricciardi W, Boccia A, La Torre G. Knowledge about pandemic flu among Italian health care workers (HCWs): an Italian survey. J Prev Med Hyg. 2011 Sep;52(3):127-30.
La Torre G, Semyonov L, Mannocci A, Boccia A. Knowledge, attitude, and behaviour of public health doctors towards pandemic influenza compared to the general population in Italy. Scand J Public Health. 2012 Feb;40(1):69-75.
La Torre G, Di Thiene D, Cadeddu C, Ricciardi W, Boccia A. Behaviours regarding preventive measures against pandemic H1N1 influenza among Italian healthcare workers, October 2009. Euro Surveill. 2009 Dec 10;14(49). pii: 19432.
Schmidt S, Saulle R, Di Thiene D, Boccia A, La Torre G. Do the quality of the trials and the year of publication affect the efficacy of intervention to improve seasonal influenza vaccination among healthcare workers?: Results of a systematic review. Hum Vaccin Immunother. 2013 Feb;9(2):349-61. Epub 2013 Jan 4.
Spadea A, Unim B, Ursillo P, Saulle R, Giraldi G, Miccoli S, Barbato A, Corda B, D'Amici AM, Boccia A, La Torre G. Efficacia di un evento formativo in materia di vaccinazione anti-influenzale sulla modifica dell'attitudine a vaccinarsi per studenti e personale sanitario. Ig Sanita Pubbl. 2013 Jul-Aug;69(4):387-402
Boccia A, Di Thiene D, De Giusti M, La Torre G. Seasonal and pandemic influenza: the role of communication and preventive strategies. J Prev Med Hyg. 2011 Sep;52(3):124-6.
La Torre G, Miccoli S, Ricciardi W. The Italian alliance for vaccination strategies: Facebook as a learning tool for preventive medicine and public health. Hum Vaccin Immunother. 2014;10(10):2910-4.
Arcaro P, Mannocci A, Saulle R, Miccoli S, Marzuillo C, La Torre G. Social marketing e sanità pubblica. Ann Ig. 2013 May-Jun;25(3):247-62.
Ethics Approval
Review articleHow to Cite
“INFLUENZA AND PNEUMOCOCCAL VACCINATION IN HEMATOLOGICAL MALIGNANCIES: A SYSTEMATIC REVIEW OF EFFICACY, EFFECTIVENESS AND SAFETY” (2016) Mediterranean Journal of Hematology and Infectious Diseases, 8, p. e2016044. doi:10.4084/mjhid.2016.044.
